Loading
Diabetes causes ~40% of kidney failure. The modern playbook — SGLT2i, GLP-1, finerenone, and BP control — has changed the outlook from 'inevitable decline' to 'manageable and often stable.'
Evidence reviewed & updated: 2026-08 — reflects the latest published trials and guidelines.
Diabetes is the #1 cause of kidney failure worldwide. The modern playbook — annual screening (UACR + eGFR), SGLT2 inhibitors, GLP-1 agonists, finerenone, and BP control — has genuinely changed outcomes: progression to kidney failure is now the exception, not the rule, for well-managed patients.
The test that matters most is the annual UACR — albuminuria appears YEARS before eGFR falls, and it's at that stage that treatment prevents decline. eGFR catches the disease later. Together (UACR + eGFR) they stage diabetic kidney disease (G + A) and set the risk level.
People with diabetes should be screened at diagnosis and annually after — early detection converts a progressive disease into a manageable one.
Modern diabetic kidney disease care stacks four evidence-based pillars: (1) SGLT2 inhibitors — dapagliflozin/empagliflozin cut progression ~40% and are first-line in CKD with albuminuria; (2) GLP-1 receptor agonists — semaglutide reduced kidney progression ~24% in FLOW; (3) finerenone — ~18% further risk reduction in FIDELIO-DKD; (4) ACEi/ARB with BP <120.
Add metformin (renal rules apply) and statins. The combination is why the old 'diabetes always progresses to dialysis' is no longer true for managed patients — the decline rate can be halved or nearly halted.
As GFR falls, insulin clearance drops — insulin needs usually decrease. Metformin is safe to eGFR 30 (don't start 30-45); below 30 it's stopped. SGLT2i and GLP-1 can reduce insulin doses substantially — recheck doses when starting them to avoid hypoglycemia.
A1C targets: moderate targets (about 7%) are safer in advanced CKD — tight targets raise hypoglycemia risk without kidney benefit. The kidney-specific targets that matter more: BP, albuminuria, and eGFR slope.
SGLT2 inhibitors (dapagliflozin, empagliflozin) are the most impactful CKD therapy advance in a decade. DAPA-CKD (NEJM 2...
Learn moreThe FLOW trial (Perkovic et al., NEJM 2024) randomized 3,533 CKD patients with T2D to semaglutide 1mg or placebo — stopp...
Learn moreFinerenone is the first nonsteroidal mineralocorticoid receptor antagonist approved for diabetic kidney disease. FIDELIO...
Learn moreSGLT2 inhibitors and GLP-1 receptor agonists have complementary, additive cardiorenal benefits. Combination use is now g...
Learn moreZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime